Sinopharm Hyundai (600420.SH) subsidiary obtained drug registration certificate for quetiapine fumarate sustained-release tablets

Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Industry Co., Ltd. (Sinopharm Industry for short), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for quetiapine fumarate sustained-release tablets approved and issued by the State Drug Administration.

Quetiapine fumarate sustained-release tablets are an atypical antipsychotic drug. It is a psychotherapeutic drug that regulates brain activity. It is mainly used to control schizophrenia and bipolar disorder. It has the effects of stabilizing mood, reducing hallucinations, and improving mental confusion, and can help patients recover normal cognitive and social function.